{
    "medicine_id": "5436b52bf5705af1aa79be06928161914f0e4328",
    "platform_id": "DB04893",
    "metadata": {
        "name": "Bepreve 15 mg 1mL Solution drops",
        "composition": "15 mg 1mL AZD3409",
        "clinical_particulars": {
            "therapeutic_indications": "For the treatment of solid tumors",
            "contraindications": {
                "disease": "NA",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "AZD3409 is a novel oral antitumor agent that acts as a prenyl transferase inhibitor It has potentially broad antitumor activity both as monotherapy and in combination with other anticancer treatments AZD3409 is a double pro drug its metabolism involves conversion to a thiol ester intermediate then intracellularly to a thiol acid active species Phase I trials were initiated January 2003 and were ongoing as of February 2004 Recent studies have shown that AZD3409 is a potent inhibitor of both prostate epithelial cell proliferation and cellular invasion without an associated bone marrow cellular toxicity",
                "excipients": "NA",
                "incompatibilities": []
            }
        },
        "revision_date": "2023-05-14"
    }
}